Your browser doesn't support javascript.
loading
CDKN2A deletion is a frequent event associated with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS).
Maura, Francesco; Dodero, Anna; Carniti, Cristiana; Bolli, Niccolò; Magni, Martina; Monti, Valentina; Cabras, Antonello; Leongamornlert, Daniel; Abascal, Federico; Diamond, Benjamin; Rodriguez-Martin, Bernardo; Zamora, Jorge; Butler, Adam; Martincorena, Inigo; Tubio, Jose M C; Campbell, Peter J; Chiappella, Annalisa; Pruneri, Giancarlo; Corradini, Paolo.
Afiliação
  • Maura F; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, United Kingdom; W
  • Dodero A; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Carniti C; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Bolli N; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Magni M; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Monti V; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Cabras A; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Leongamornlert D; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire.
  • Abascal F; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire.
  • Diamond B; Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Rodriguez-Martin B; CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela.
  • Zamora J; CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela.
  • Butler A; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire.
  • Martincorena I; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire.
  • Tubio JMC; CIMUS - Molecular Medicine and Chronic Diseases Research Centre, University of Santiago de Compostela.
  • Campbell PJ; The Cancer, Ageing and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire.
  • Chiappella A; Present address: Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Department of Hematology Azienda Ospedaliera Città della Salute e della Scienza, Turin.
  • Pruneri G; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
  • Corradini P; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan. paolo.corradini@unimi.it.
Haematologica ; 106(11): 2918-2926, 2021 Nov 01.
Article em En | MEDLINE | ID: mdl-33054126
ABSTRACT
Nodal peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) remains a diagnosis encompassing a heterogenous group of PTCL cases not fitting criteria for more homogeneous subtypes. They are characterized by a poor clinical outcome when treated with anthracycline-containing regimens. A better understanding of their biology could improve prognostic stratification and foster the development of novel therapeutic approaches. Recent targeted and whole exome sequencing studies have shown recurrent copy number abnormalities (CNAs) with prognostic significance. Here, investigating 5 formalin-fixed, paraffin embedded cases of PTCL-NOS by whole genome sequencing (WGS), we found a high prevalence of structural variants and complex events, such as chromothripsis likely responsible for the observed CNAs. Among them, CDKN2A and PTEN deletions emerged as the most frequent aberration, as confirmed in a final cohort of 143 patients with nodal PTCL. The incidence of CDKN2A and PTEN deletions among PTCL-NOS was 46% and 26%, respectively. Furthermore, we found that co-occurrence of CDKN2A and PTEN deletions is an event associated with PTCL-NOS with absolute specificity. In contrast, these deletions were rare and never co-occurred in angioimmunoblastic and anaplastic lymphomas. CDKN2A deletion was associated with shorter overall survival in multivariate analysis corrected by age, IPI, transplant eligibility and GATA3 expression (adjusted HR =2.53; 95% CI 1.006-6.3; p=0.048). These data suggest that CDKN2A deletions may be relevant for refining the prognosis of PTCL-NOS and their significance should be evaluated in prospective trials.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células T Periférico / Inibidor p16 de Quinase Dependente de Ciclina Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células T Periférico / Inibidor p16 de Quinase Dependente de Ciclina Idioma: En Ano de publicação: 2021 Tipo de documento: Article